Trial Profile
A study evaluating safety and efficacy of Apatinib for advanced non small cell lung cancer in the second- or third-line setting.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record